J. Goldman & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

J. Goldman & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-37,761	Closed	-$3.01M	–	540
2022 Q2	$3.01M	Buy	+37,761	New	+$3.58M	0.15%	164
2020 Q4	–	Sell	-44,764	Closed	-$3.48M	–	527
2020 Q3	$3.48M	Buy	44,764 +26,457	+145%	+$1.82M	0.24%	128
2020 Q2	$1.02M	Sell	18,307 -22,557	-55%	-$965K	0.06%	194
2020 Q1	$1.21M	Buy	+40,864	New	+$1.38M	0.15%	131
2016 Q4	–	Sell	-206,100	Closed	-$3.74M	–	434
2016 Q3	$3.74M	Buy	+206,100	New	+$4.03M	0.21%	138
2014 Q4	–	Sell	-113,750	Closed	-$1.4M	–	312
2014 Q3	$1.4M	Buy	+113,750	New	+$1.32M	0.08%	205
2014 Q1	–	Sell	-667,592	Closed	-$5.09M	–	321
2013 Q4	$5.09M	Buy	667,592 +105,542	+19%	+$569K	0.64%	36
2013 Q3	$1.88M	Buy	+562,050	New	+$1.48M	0.18%	164

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

J. Goldman & Co's HZNP Position: Q3 2022 in Review

J. Goldman & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 37,761 shares — an estimated $3.01M sold.

J. Goldman & Co first reported a position in HZNP in Q3 2013 and held it in 8 quarters. The position peaked at $5.09M in Q4 2013. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

J. Goldman & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
J. Goldman & Co sold 37,761 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $3.01M.
J. Goldman & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 8 quarters.
J. Goldman & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.09M in Q4 2013.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.